Abstract 31P
Background
Cervical cancer (CC) is the fourth most common type of cancer among women worldwide. Considering that the early diagnosis of cervical intraepithelial neoplasia (CIN) is the main strategy to improve the prognosis of patients, new methodologies based on molecular analyzes performed on liquid biopsy samples, represent promising alternatives for minimally invasive biomarkers. miRNAs have been shown their role as non-invasive biomarkers, providing a wide perspective for personalized treatment and early diagnosis of cervical cancer through liquid-based cytology (LBC). However, more research is under way to identify miRNA signatures that can be implemented in clinical practice specially for early detection. In this study, we aimed to identify molecular signatures of miRNAs in cervical precursor lesions (CIN 2 and CIN 3) from LBC and their interaction with molecular pathways related to CC in a prospective study.
Methods
We analyzed 96 LBC cervical samples, that were divided into two groups: the case group was composed of women diagnosed with CIN 2 and CIN3 (n = 48); the control group corresponded to women without cervical precursor lesions (n = 48). We performed miRNA expression profiling using the nCounter® miRNA Expression Assay (NanoString Technology), which evaluated 800 targets. A functional analysis in silico was performed by mirDIP and enrichment were performed using Cytoscape with the Reactome plugin.
Results
We identified 54 miRNAs that were differentially expressed between case and control groups (p ≤ 0.05). Using logistic regression analysis, we identified a signature composed of five miRNAs, with a fold change ≥ 1.5 and FDR-corrected p-value of ≤ 0.05, of which two were up-regulated and three were down-regulated. The signature had a predictive value with an AUC of 0.90. Furthermore, we found 26 miRNA target genes for four of the five identified miRNAs, mainly related to pathways in cancer, RNA Polymerase II Transcription, RhoA signaling pathway, and PI3K-Akt signaling pathway.
Conclusions
This study demonstrated that those miRNAs could be used as non-invasive biomarkers in LBC samples, once they were able to distinguish CIN 2 and CIN3 patients from healthy women and regulate important molecular pathways of onset carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Barretos Cancer Hospital.
Funding
Programa Nacional de Apoio à Atenção Oncológica.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09